Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Emerging
Primary summary from verified readiness
- Confidence
- 72% · stale
- Computed at
- 2026-08-20T10:54:44.663087+00:00
- Claimed
- 35
- Reported
- 35
- Verified
- 32
- Gap
- +3
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed leads verified
Evidence strength Strong
Decision
What the current evidence supports
Human editorial judgment · 2026-08-20
Too early to adopt
- Why
- First-in-human dosing plus a $80M Series D (Apr 2026) make this a genuine milestone, but it is an 18-patient Phase 1 safety trial of a modality whose central oncogenic-vs-rejuvenation risk is still unresolved in the literature; nothing is adoptable, only watchable
- Next
- Track the NCT07290244 Day-112 safety / dose-limiting-toxicity readout (primary completion ~May 2027) and any exploratory visual-function signal; do not treat partial reprogramming as a deployable modality until a clean human safety window is demonstrated
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 13
- Tier 1
- 0
- Tier 2
- 0
- Tier 3
- 13
- Supports
- 5
- Contradicts
- 2
- Context
- 6
- Latest observed
- 2026-06-09
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Initial public reading
- 2026-07-19 Reading moved from emerging to emerging.